ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
化学式:
H2NCH2C6H10CO2H
CAS番号:
分子量:
157.21
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
2207452
InChI
1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-
SMILES string
NC[C@H]1CC[C@@H](CC1)C(O)=O
InChI key
GYDJEQRTZSCIOI-LJGSYFOKSA-N
grade
pharmaceutical primary standard
API family
tranexamic acid
manufacturer/tradename
USP
mp
>300 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... PLG(5340)
類似した製品をお探しですか？ 訪問 製品比較ガイド
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Application
Tranexamic acid USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Tranexamic Acid Tablets
- Tranexamic Acid Injection
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
保管分類
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
1672745-200MG:
jan
Zhi-Jun Li et al.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 22(9), 1950-1957 (2013-05-10)
The present meta-analysis aimed at assessing the effectiveness and safety of tranexamic acid (TXA) in reducing blood loss and transfusion in spinal surgery. Systematic searches of all studies published through March 2012 were identified from PubMed, EMBase, Cochrane library, Science
Baohui Yang et al.
PloS one, 8(2), e55436-e55436 (2013-02-21)
Tranexamic acid (TXA) is well-established as a versatile oral, intramuscular, and intravenous (IV) antifibrinolytic agent. However, the efficacy of IV TXA in reducing perioperative blood transfusion in spinal surgery is poorly documented. We conducted a meta-analysis of randomized controlled trials
Chih-Hsiang Chang et al.
Clinical orthopaedics and related research, 472(5), 1552-1557 (2014-01-05)
Systemic tranexamic acid can decrease blood loss and rates of transfusion in patients undergoing total hip arthroplasty (THA). However, the efficacy of topical tranexamic acid in THA has only recently been characterized in a small number of studies. The purpose
K Ker et al.
The British journal of surgery, 100(10), 1271-1279 (2013-07-11)
Tranexamic acid (TXA) reduces blood transfusion in surgery but the extent of the reduction in blood loss and how it relates to the dose of TXA is unclear. A systematic review of randomized trials was performed. Data were extracted on
Chee Ching Chan et al.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 270(2), 735-748 (2012-09-22)
Post-tonsillectomy haemorrhage is a serious complication that can lead to death despite the fact that tonsillectomy is one of the commonest procedures performed in otolaryngology. Post-operative haemorrhage can be reduced by a potent antifibrinolytic agent such as tranexamic acid (TXA).
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）